NEIMETH INTERNATIONAL PHARMACEUTICALS PLC

FINANCIAL STATEMENTS 30 JUNE 2022

NEIMETH INTERNATIONAL PHARMACEUTICALS PLC

FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 30 JUNE 2022

Contents

Page

Statement of financial position

1

Statement of profit or loss and other comprehensive income

2-3

Statement of changes in equity

4

Statement of cash flows

5

Free Float Assessment

6

Notes to the financial statements

7-47

Other national disclosures:

Statement of value added

46

Financial summary

47

NEIMETH INTERNATIONAL PHARMACEUTICALS PLC

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE PERIOD ENDED 30 JUNE 2022

30-Jun-22

30-Jun-21

Note

N'000

N'000

Turnover

8

1,826,865

1,991,296

Cost of sales

9

(1,103,288)

(1,064,285)

Gross profit / (Loss)

723,577

927,011

Other income

10

18,926

16,638

Marketing and distribution expenses

11

(437,415)

(394,744)

Administrative expenses

12

(412,424)

(346,637)

Exchange Gain / (Loss)

13

94,694

(3,994)

Operating profit

(12,643)

198,274

Finance costs

14

(121,007)

(113,446)

(Loss)/Profit before taxation

(133,652)

84,828

Income tax expense

28

-

-

(Loss)/ Profit for the year from continued operation

(133,652)

84,828

Other comprehensive income

Gain on available for sale assets

-

-

Total other comprehensive income

-

-

Total comprehensive (Loss)/Profit

(133,652)

84,828

Basic (loss)/earnings per share

32

(7)

4

The explanatory notes and statement of significant accounting policies form an integral part of these financial statements.

2

NEIMETH INTERNATIONAL PHARMACEUTICALS PLC

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE PERIOD ENDED 30 JUNE 2022

Quarter 2

YTD

Quarter 2

YTD

Ended

ended

Ended

ended

Apr - June ' 22

30-Jun-22

Apr - June '21

30-Jun-21

Note

N'000

N'000

N'000

N'000

Turnover

8

841,617

1,826,865

709,720

1,991,296

Cost of sales

9

(543,755)

(1,103,288)

(323,076)

(1,064,285)

Gross profit / (Loss)

297,862

723,577

386,644

927,011

Other income

10

6,477

18,926

5,439

16,638

Marketing and distribution expenses

11

(140,818)

(437,415)

(122,626)

(394,744)

Administrative expenses

12

(93,548)

(412,424)

(120,306)

(346,637)

Exchange Gain/ (Loss)

13

91,238

94,694

(21,499)

(3,994)

Operating profit

161,211

(12,643)

127,652

198,274

Finance costs

14

(85,929)

(121,007)

(71,129)

(113,446)

(Loss)/Profit before taxation

75,282

(133,652)

56,523

84,828

Income tax expense

28

-

-

(Loss)/ Profit for the year from continued operation

75,282

(133,652)

56,523

84,828

Other comprehensive income

Gain on available for sale assets

-

-

-

Total other comprehensive income

-

-

-

Total comprehensive (Loss)/Profit

75,282

(133,652)

56,523.00

84,827.96

Basic (loss)/earnings per share

32

3.96

(7.04)

2.98

1,901,866.00

The explanatory notes and statement of significant accounting policies form an integral part of these financial statements.

3

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Neimeth International Pharmaceuticals plc published this content on 29 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 July 2022 17:54:52 UTC.